Open letter to Europe by André Rogaczewski CEO and co-founder of Netcompany: Europe must stand tall
23.4.2025 06:30:00 CEST | Business Wire | Press release
On the night of 22 April, the Statue of Liberty at Pont de Grenelle in Paris was illuminated with the message: “Stand Tall Europe”. Once a gift symbolising the transatlantic alliance and shared ideals of the West, the statue now stands as a reminder of a fellowship through centuries that is put under heavy pressure.
The following is an open letter by André Rogaczewski CEO and co-founder of Netcompany:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422921783/en/
Statue of Liberty at Pont de Grenelle last night in Paris – Iluminated with the message ”Stand Tall Europe”.
Europeans,
This is your digital awakening.
We all know that leading technologically is paramount for competitiveness and the creation of growth, prosperity, and welfare.
Europe’s digital backbone is to a large extent built on systems we don’t necessarily control. From data centers to cloud systems – in the applications and algorithms that shape our decisions.
While we rely on digital services in all our core societal areas— communication, financial services, welfare benefits, pensions, healthcare, even elections—the digital applications and infrastructures behind are too often dependent on non-European systems.
What we need is a response. To protect our individual rights, and shape a digital European ecosystem rooted in our own democratic values – not those imposed by people who no longer necessarily share our beliefs.
That’s why Netcompany launched a campaign on the night of 22 April by illuminating the Statue of Liberty in Paris with the message: “Stand Tall Europe”.
We chose the Statue of Liberty because it stands as a symbol of freedom, justice, the end of oppression, and opportunity for all. A gift from Europe to the US symbolising the values we created together and used to share. It seems now that Europe herself alone is facing the challenge of protecting those same ideals in a digital world.
Where the Statue of Liberty lifts a torch, Europe’s task today is to light the digital path forward—by asserting digital sovereignty, defending rights online, and building our own trusted secure systems and applications that our societies can rely on and prosper with.
We must embrace the digital revolution, establish more European datacenters, set up trusted age-verification systems to protect our children, and ensure our voters are not filled with digital propaganda.
We must quickly build trustworthy, robust, fair, and transparent applications and systems showing everyone else that responsible digital transformation is the way to create world-leading innovation, growth and progress.
That means offensively using AI designed with European values and transparency to create efficient European private and public administration. It means developing intelligent digital twins for our physical infrastructure across all industries to uniquely optimise European businesses. In fact, we must build world leading digital applications for Europe to become a leading region of the world.
We are calling for more European solutions—built by European companies, accountable to European citizens.
Europe’s future prosperity and growth depends on it and hence it also depends on our ability to attract, develop, and unite diverse world-class talent from everywhere.
We must make this continent the most attractive destination for the world’s sharpest minds.
This is also a call for all of you who want to contribute to the European digital awakening, wherever you are. We need you.
There’s no quick fix. But we are ready. We believe in a digital future where Europe owns more of its systems, protects its citizens, and leads with integrity.
Let’s take back the future.
Yours sincerely,
André Rogaczewski
CEO and co-founder of Netcompany
About André Rogaczewski
André Rogaczewski founded Netcompany in 2000 and has overseen its evolution into one of Europe’s fastest growing and most successful IT services companies, with a global headcount of +8,250 talented employees across +10 European countries.
With his technical background, a master's degree in computer science from Aalborg University and a true vision for society’s digital future, he has led the company through tremendous growth and built a unique delivery model unmatched elsewhere in the IT industry. André was born in Poland and grew up in Aalborg, Denmark.
About Netcompany
Founded in 2000 in Copenhagen, Denmark, Netcompany provides essential IT solutions for both societal and business needs, aiding our private and public clients in their digital evolution towards a more efficient and sustainable future.
Our team of skilled professionals drives sustainable innovation, consistently advancing and expanding our impact - one solution at a time.
By building flexible, scalable and secure digital solutions, we help Europe lead the way towards responsible digitalisation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250422921783/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom